Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $86,844 - $110,380
-200 Reduced 0.7%
28,500 $15.5 Million
Q2 2024

Aug 14, 2024

SELL
$356.01 - $451.55 $1.67 Million - $2.12 Million
-4,700 Reduced 14.07%
28,700 $12.3 Million
Q1 2024

May 15, 2024

SELL
$356.95 - $413.29 $18.3 Million - $21.2 Million
-51,200 Reduced 60.52%
33,400 $13.2 Million
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $15.2 Million - $22.7 Million
44,800 Added 112.56%
84,600 $32.2 Million
Q3 2023

Nov 14, 2023

SELL
$369.35 - $548.43 $1.74 Million - $2.58 Million
-4,700 Reduced 10.56%
39,800 $19.6 Million
Q2 2023

Aug 14, 2023

BUY
$360.14 - $422.58 $2.27 Million - $2.66 Million
6,300 Added 16.49%
44,500 $17.3 Million
Q1 2023

May 15, 2023

BUY
$334.23 - $403.65 $3.44 Million - $4.16 Million
10,300 Added 36.92%
38,200 $14.2 Million
Q4 2022

Feb 14, 2023

BUY
$342.17 - $402.31 $4.55 Million - $5.35 Million
13,300 Added 91.1%
27,900 $10.6 Million
Q3 2022

Nov 14, 2022

SELL
$343.2 - $395.75 $4.56 Million - $5.26 Million
-13,300 Reduced 47.67%
14,600 $5.16 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.